SAGIMET BIOSCIENCES INC SERIES A (SGMT) — insider trading
Health Care · NASDAQ
SAGIMET BIOSCIENCES INC SERIES A (SGMT) has 24 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 24 (latest 2026-08-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George | Director | Option exercise / conversion (derivative) | 24,369 | — | $0 | Form 4 |
| 2026-08-14 | Kemble George | Director | Option exercise / conversion (derivative) | 326,618 | — | $0 | Form 4 |
| 2026-08-14 | Kemble George | Director | Open-market sale | 350,987 | $10.23 | $3.59M | Form 4 |
| 2026-08-14 | Kemble George | Director | Option exercise / conversion | 24,369 | $6.36 | $155.0K | Form 4 |
| 2026-08-14 | Kemble George | Director | Option exercise / conversion | 326,618 | $6.36 | $2.08M | Form 4 |
| 2026-08-11 | Kemble George | Director | Option exercise / conversion (derivative) | 10,455 | — | $0 | Form 4 |
| 2026-08-11 | Kemble George | Director | Option exercise / conversion (derivative) | 9,751 | — | $0 | Form 4 |
| 2026-08-11 | Kemble George | Director | Open-market sale | 20,206 | $9.95 | $201.1K | Form 4 |
| 2026-08-11 | Kemble George | Director | Option exercise / conversion | 10,455 | $6.36 | $66.5K | Form 4 |
| 2026-08-11 | Kemble George | Director | Option exercise / conversion | 9,751 | $6.36 | $62.0K | Form 4 |
| 2026-07-20 | Kemble George | Director | Open-market sale | 18,844 | $7.46 | $140.5K | Form 4 |
| 2026-07-20 | Rozek Elizabeth | Officer (Chief Legal & Admin. Officer) | Open-market sale | 10,545 | $7.76 | $81.8K | Form 4 |
| 2026-07-20 | Happel David | Director, Officer (President & CEO) | Open-market sale | 64,051 | $7.76 | $497.1K | Form 4 |
| 2026-06-12 | Phillips Anne M. | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-06-12 | Kemble George | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-06-12 | GRAMMER ELIZABETH A | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-06-12 | Jarrett Jennifer | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-06-12 | Hoelscher Paul W. | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-06-12 | SEIDENBERG BETH C | Director | Grant / award / vesting (derivative) | 39,567 | — | $0 | Form 4 |
| 2026-05-28 | Happel David | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
| 2026-05-28 | Rozek Elizabeth | Officer (Chief Legal & Admin. Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-05-28 | Grauer Andreas | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-05-28 | Chauche Thierry | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-04-20 | Grauer Andreas | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 264,759 | — | $0 | Form 4 |
Ask the chat about SGMT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SAGIMET BIOSCIENCES INC SERIES A (SGMT).
Last updated 2026-08-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.